Placeholder Banner

BIO Comments on Proposed Settlement Agreement Between EPA and Philadelphia Energy Solutions on RFS Obligations

March 26, 2018

BIO submitted comments to the U.S. Department of Justice on the proposed Consent Decree and Environmental Settlement Agreement with the United States Bankruptcy Court for the District of Delaware in PES HOLDINGS LLC., ET AL., Civil Action No. 18-10122 (Bankr. D. Del.), IN RE: PES Holdings, LLC., et al., D.J. Ref. No. 90-5-2-1-10993/11.

BIO is greatly concerned by DOJ and the U.S. Environmental Protection Agency’s Settlement Agreement with PES Holdings, LLC and its debtors, including Philadelphia Energy Solutions Refining and Marketing LLC, to resolve a dispute about the obligations and liabilities of PESRM and related parties under the Clean Air Act’s Renewable Fuel Standard program.

The RFS has spurred investment, research and development, and commercialization of advanced and cellulosic biofuels. The RFS has enabled the advanced biofuels industry to make significant investments to meet the requirements of the RFS.

The Settlement Agreement undermines the goals of the RFS by allowing refiners to escape their RIN obligations under the law. The record shows the debtors shirked compliance with the RFS program while paying unwarranted dividends to shareholders.

BIO requests EPA and DOJ reconsider its Settlement Agreement with the debtors and PESRM.

Download Full Comments Below
IN RE PES Holdings LLC. Et Al. D.J. Ref. No. 90-5-2-1-10993 1 - Biotechn...
Comments FIled on the Proposed Settlement Agreement for PES
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
The Biotechnology Innovation Organization (BIO) is pleased to respond to the U.S. Department of Agriculture’s (USDA) Solicitation of Input from Stakeholders on Agricultural Innovations. BIO applauds USDA for taking a proactive approach and seeking…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…